Building a hit list for the fight against metastatic castration resistant prostate cancer

Jonathan D. Strope; Douglas K. Price; William D. Figg

doi:10.1080/15384047.2016.1139270

Building a hit list for the fight against metastatic castration resistant prostate cancer

Jonathan D. Strope
, Douglas K. Price
, William D. Figg^*

^*Corresponding author for this work

Surgery

Research output: Contribution to journal › Article › peer-review

4 Scopus citations

Abstract

Identification of genetic alterations in Metastatic Castration Resistant Prostate Cancer (mCRPC) may provide scientists and clinicians with a list of new targets for drug research and development. Recently published in Cell, Robinson et al. present the first look at genetic data from mCRPC lesions gathered over multiple years and from many institutions.

Original language	English
Pages (from-to)	231-232
Number of pages	2
Journal	Cancer Biology and Therapy
Volume	17
Issue number	3
DOIs	https://doi.org/10.1080/15384047.2016.1139270
State	Published - 3 Mar 2016

Keywords

Actionable tumors
PTEN
androgen deprivation
androgen receptor
genetic alterations
mCRPC
translational medication

Access to Document

10.1080/15384047.2016.1139270

Cite this

@article{4753dd7024bc4f4db7b86796cb01faff,

title = "Building a hit list for the fight against metastatic castration resistant prostate cancer",

abstract = "Identification of genetic alterations in Metastatic Castration Resistant Prostate Cancer (mCRPC) may provide scientists and clinicians with a list of new targets for drug research and development. Recently published in Cell, Robinson et al. present the first look at genetic data from mCRPC lesions gathered over multiple years and from many institutions.",

keywords = "Actionable tumors, PTEN, androgen deprivation, androgen receptor, genetic alterations, mCRPC, translational medication",

author = "Strope, \{Jonathan D.\} and Price, \{Douglas K.\} and Figg, \{William D.\}",

note = "Publisher Copyright: {\textcopyright} , This article not subject to US copyright law.",

year = "2016",

month = mar,

day = "3",

doi = "10.1080/15384047.2016.1139270",

language = "English",

volume = "17",

pages = "231--232",

journal = "Cancer Biology and Therapy",

issn = "1538-4047",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

TY - JOUR

T1 - Building a hit list for the fight against metastatic castration resistant prostate cancer

AU - Strope, Jonathan D.

AU - Price, Douglas K.

AU - Figg, William D.

N1 - Publisher Copyright: © , This article not subject to US copyright law.

PY - 2016/3/3

Y1 - 2016/3/3

N2 - Identification of genetic alterations in Metastatic Castration Resistant Prostate Cancer (mCRPC) may provide scientists and clinicians with a list of new targets for drug research and development. Recently published in Cell, Robinson et al. present the first look at genetic data from mCRPC lesions gathered over multiple years and from many institutions.

AB - Identification of genetic alterations in Metastatic Castration Resistant Prostate Cancer (mCRPC) may provide scientists and clinicians with a list of new targets for drug research and development. Recently published in Cell, Robinson et al. present the first look at genetic data from mCRPC lesions gathered over multiple years and from many institutions.

KW - Actionable tumors

KW - PTEN

KW - androgen deprivation

KW - androgen receptor

KW - genetic alterations

KW - mCRPC

KW - translational medication

UR - https://www.scopus.com/pages/publications/84961214960

U2 - 10.1080/15384047.2016.1139270

DO - 10.1080/15384047.2016.1139270

M3 - Article

C2 - 26822877

AN - SCOPUS:84961214960

SN - 1538-4047

VL - 17

SP - 231

EP - 232

JO - Cancer Biology and Therapy

JF - Cancer Biology and Therapy

IS - 3

ER -

Building a hit list for the fight against metastatic castration resistant prostate cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this